A Study of the Efficacy of RWJ-333369 in the Prevention of Migraine
The purpose of this study is to evaluate whether RWJ-333369 is a safe and effective treatment in reducing the number of migraine headaches when added to a person's usual medications for acute migraine headache relief.
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
|Official Title:||A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging, Multicenter Study of the Efficacy of RWJ-333369 in the Prophylaxis of Migraine|
- Percent reduction in the average monthly migraine frequency from the baseline period to the entire double-blind treatment phase.
|Study Start Date:||March 2002|
|Study Completion Date:||February 2006|
|Primary Completion Date:||February 2006 (Final data collection date for primary outcome measure)|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00109083
Show 25 Study Locations
|Study Director:||Johnson & Johnson Pharmaceutical R & D, L.L.C., Clinical Trial||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|